Lupin in alliance with Natco receives FDA approval for Bosentan Tablets Kumar Jeetendra | April 30, 2019 Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. rnrn Lupin …
Cipla appoints Dr Raju Mistry as Global Chief People Officer Kumar Jeetendra | April 22, 2019 Mumbai, April 22, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces the appointment of Dr. Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla. Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors …
Lupin receives FDA approval for Testosterone Gel Kumar Jeetendra | April 11, 2019 Mumbai, Baltimore, April 11, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s (AbbVie) AndroGel 1.62%. Lupin’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), …
Lupin launches Fluoxetine Tablets USP Kumar Jeetendra | April 10, 2019 Mumbai, Baltimore, April 10, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Fluoxetine Tablets USP, 60mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the …
Emcure launches worlds first generic Eribulin for treatment of metastatic breast cancer Kumar Jeetendra | April 4, 2019 Eribulin will be available in India at approximately 40% cost of the innovator brand Emcure Pharmaceuticals, a leading integrated global pharmaceutical company from India today announced the launch of the world’s first generic version of Eisai Pharmaceutical’s Halaven (Eribulin) for the treatment of metastatic breast cancer (MBC). Emcure will be marketing the drug under brand …
Lupin Bioresearch Centre completes fifth successful US FDA inspection Kumar Jeetendra | April 3, 2019 Mumbai, Baltimore, April 03, 2019: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. rnrnThis is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility. rnrnLupin …
Lupin appoints Ms Christine Mundkur as an Independent Director Kumar Jeetendra | April 1, 2019 Mumbai, April 1, 2019: Pharma major Lupin Limited (Lupin) announced today the appointment of Ms. Christine Mundkur as an Independent Director with immediate effect. Ms. Mundkur most recently served as Chief Executive Officer and Non-voting Chairman of the Board of Directors for Impopharma Inc, a developer of complex formulations focused on inhalation pharmaceutical products. While …
Imaweld Heat Sealable Thermoplastic Elastomer Tube by Amipolymer Pvt Ltd Kumar Jeetendra | March 2, 2019 Imaweld® is thermoplastic elastomer opaque tubing designed for fluid transfer in pharmaceutical and biotech applications. Imaweld® is specially formulated which meets requirement of pharmaceutical industries with superiority compare to PVC and silicone. Imaweld® complies with FDA 21 CFR 177.2600, USP Class VI & ISO 10993. It is manufactured & packaged under GMP guidelines in dust …
Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases Kumar Jeetendra | February 25, 2019 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Wellthy Therapeutics Private Limited (“Wellthy Therapeutics”) today announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology. Under the agreement, a multi-lingual …
Cole Parmer launches its biggest Pharma Resource Book Dedicated to Pharma and Biopharma customers needs from research to production Kumar Jeetendra | February 12, 2019 Cole-Parmer, a leading manufacturer and supplier of laboratory and industrial products, instrumentation, and supplies recently launched its biggest Pharma Resource Book 2019-20, dedicated to meet application needs of Pharmaceutical and Biopharma customers. For biopharma product development, the pharma resource book addresses the pain areas of the customers such as compliance, SOP concerns, customized solutions, validation …
Cipla receives final approval for generic version of Eli Lilly Cos Adcirca Kumar Jeetendra | February 7, 2019 Mumbai, India, February 7, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA). Cipla’s Tadalafil Tablets 20mg is AB-rated generic therapeutic …
Cipla receives final approval for generic version of Pfizers Depo Provera Kumar Jeetendra | January 28, 2019 Mumbai, India, January 28, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA). Cipla’s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic …
